32
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Loss-of-function nuclear factor κB subunit 1 (NFKB1) variants are the most common monogenic cause of common variable immunodeficiency in Europeans

      research-article
      , MD a , b , , , PhD c , d , , , MRCP, PhD e , , , MPhil c , d , , BSc a , b , , MRCP, FRCPath, PhD f , , PhD c , d , , PhD c , d , , PhD f , , MRCP, PhD f , , MRCP, FRCPath, BSc g , , MRCP, FRCPath, PhD f , , FRCP, FRCPath, PhD h , , MD, PhD i , , MD e , , MD j , , PhD c , , MD, PhD k , , PhD l , , PhD b , , MSc m , , PhD m , , PhD c , d , , BSc c , d , , BSc c , d , , PhD c , d , , MD, PhD n , , PhD, FMedSci f , , MRCP, FRCPath, PhD f , ∗∗ , , , MD, PhD a , b , k , , , NIHR BioResource–Rare Diseases Consortium
      The Journal of Allergy and Clinical Immunology
      Mosby
      B cells, common variable immunodeficiency, nuclear factor κB1, CFSE, Carboxyfluorescein succinimidyl ester, CVID, Common variable immunodeficiency, LOF, Loss-of-function, NF-κB, Nuclear factor κB, NFKB1, Nuclear factor κB subunit 1, NIHRBR-RD, NIHR BioResource–Rare Diseases, PID, Primary immunodeficiency disease, PML, Progressive multifocal leukoencephalopathy, RHD, Rel homology domain, VEP, Variant effect predictor

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The genetic cause of primary immunodeficiency disease (PID) carries prognostic information.

          Objective

          We conducted a whole-genome sequencing study assessing a large proportion of the NIHR BioResource–Rare Diseases cohort.

          Methods

          In the predominantly European study population of principally sporadic unrelated PID cases (n = 846), a novel Bayesian method identified nuclear factor κB subunit 1 (NFKB1) as one of the genes most strongly associated with PID, and the association was explained by 16 novel heterozygous truncating, missense, and gene deletion variants. This accounted for 4% of common variable immunodeficiency (CVID) cases (n = 390) in the cohort. Amino acid substitutions predicted to be pathogenic were assessed by means of analysis of structural protein data. Immunophenotyping, immunoblotting, and ex vivo stimulation of lymphocytes determined the functional effects of these variants. Detailed clinical and pedigree information was collected for genotype-phenotype cosegregation analyses.

          Results

          Both sporadic and familial cases demonstrated evidence of the noninfective complications of CVID, including massive lymphadenopathy (24%), unexplained splenomegaly (48%), and autoimmune disease (48%), features prior studies correlated with worse clinical prognosis. Although partial penetrance of clinical symptoms was noted in certain pedigrees, all carriers have a deficiency in B-lymphocyte differentiation. Detailed assessment of B-lymphocyte numbers, phenotype, and function identifies the presence of an increased CD21 low B-cell population. Combined with identification of the disease-causing variant, this distinguishes between healthy subjects, asymptomatic carriers, and clinically affected cases.

          Conclusion

          We show that heterozygous loss-of-function variants in NFKB1 are the most common known monogenic cause of CVID, which results in a temporally progressive defect in the formation of immunoglobulin-producing B cells.

          Graphical abstract

          Related collections

          Most cited references29

          • Record: found
          • Abstract: found
          • Article: not found

          Comparative Protein Structure Modeling Using MODELLER.

          Functional characterization of a protein sequence is one of the most frequent problems in biology. This task is usually facilitated by accurate three-dimensional (3-D) structure of the studied protein. In the absence of an experimentally determined structure, comparative or homology modeling can sometimes provide a useful 3-D model for a protein that is related to at least one known protein structure. Comparative modeling predicts the 3-D structure of a given protein sequence (target) based primarily on its alignment to one or more proteins of known structure (templates). The prediction process consists of fold assignment, target-template alignment, model building, and model evaluation. This unit describes how to calculate comparative models using the program MODELLER and discusses all four steps of comparative modeling, frequently observed errors, and some applications. Modeling lactate dehydrogenase from Trichomonas vaginalis (TvLDH) is described as an example. The download and installation of the MODELLER software is also described. Curr. Protoc. Bioinform. 47:5.6.1-5.6.32. © 2014 by John Wiley & Sons, Inc. Copyright © 2014 John Wiley & Sons, Inc.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.

            Rituximab improves outcomes for persons with lymphoproliferative disorders and is increasingly used to treat immune-mediated illnesses. Recent reports describe 2 patients with systemic lupus erythematosus and 1 with rheumatoid arthritis who developed progressive multifocal leukoencephalopathy (PML) after rituximab treatment. We reviewed PML case descriptions among patients treated with rituximab from the Food and Drug Administration, the manufacturer, physicians, and a literature review from 1997 to 2008. Overall, 52 patients with lymphoproliferative disorders, 2 patients with systemic lupus erythematosus, 1 patient with rheumatoid arthritis, 1 patient with an idiopathic autoimmune pancytopenia, and 1 patient with immune thrombocytopenia developed PML after treatment with rituximab and other agents. Other treatments included hematopoietic stem cell transplantation (7 patients), purine analogs (26 patients), or alkylating agents (39 patients). One patient with an autoimmune hemolytic anemia developed PML after treatment with corticosteroids and rituximab, and 1 patient with an autoimmune pancytopenia developed PML after treatment with corticosteroids, azathioprine, and rituximab. Median time from last rituximab dose to PML diagnosis was 5.5 months. Median time to death after PML diagnosis was 2.0 months. The case-fatality rate was 90%. Awareness is needed of the potential for PML among rituximab-treated persons.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Transcriptional regulation via the NF-kappaB signaling module.

              Stimulus-induced nuclear factor-kappaB (NF-kappaB) activity, the central mediator of inflammatory responses and immune function, comprises a family of dimeric transcription factors that regulate diverse gene expression programs consisting of hundreds of genes. A family of inhibitor of kappaB (IkappaB) proteins controls NF-kappaB DNA-binding activity and nuclear localization. IkappaB protein metabolism is intricately regulated through stimulus-induced degradation and feedback re-synthesis, which allows for dynamic control of NF-kappaB activity. This network of interactions has been termed the NF-kappaB signaling module. Here, we summarize the current understanding of the molecular structures and biochemical mechanisms that determine NF-kappaB dimer formation and the signal-processing characteristics of the signaling module. We identify NF-kappaB-kappaB site interaction specificities and dynamic control of NF-kappaB activity as mechanisms that generate specificity in transcriptional regulation. We discuss examples of gene regulation that illustrate how these mechanisms may interface with other transcription regulators and promoter-associated events, and how these mechanisms suggest regulatory principles for NF-kappaB-mediated gene activation.
                Bookmark

                Author and article information

                Contributors
                Journal
                J Allergy Clin Immunol
                J. Allergy Clin. Immunol
                The Journal of Allergy and Clinical Immunology
                Mosby
                0091-6749
                1097-6825
                1 October 2018
                October 2018
                : 142
                : 4
                : 1285-1296
                Affiliations
                [a ]Department of Pediatric Hematology, Immunology and Infectious Diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, The Netherlands
                [b ]Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands
                [k ]Department of Internal Medicine, Academic Medical Center, Amsterdam, The Netherlands
                [c ]Department of Haematology, University of Cambridge, Cambridge, United Kingdom
                [f ]Department of Medicine, University of Cambridge, Cambridge, United Kingdom
                [d ]NHS Blood and Transplant Cambridge, Cambridge Biomedical Campus, Cambridge, United Kingdom
                [o ]NIHR BioResource–Rare Diseases, Cambridge Biomedical Campus, Cambridge, United Kingdom
                [e ]Department of Immunology, Royal Free London NHS Foundation Trust, University College London Institute of Immunity and Transplantation, London, United Kingdom
                [g ]Department of Immunology, Queen Elizabeth University Hospital, Glasgow, United Kingdom
                [h ]Department of Immunology, Royal Surrey County Hospital, Guildford, United Kingdom
                [i ]Department of Immunology, Barts Health NHS Trust, London, United Kingdom
                [j ]Department of Clinical Immunology, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), Paris, France
                [l ]Department of Blood Cell Research, Sanquin Research, Amsterdam, The Netherlands
                [m ]Department of Plasma Proteins, Sanquin Research, Amsterdam, The Netherlands
                [n ]Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health and Great Ormond Street Hospital NHS Trust London, London, United Kingdom
                Author notes
                []Corresponding author: Taco W. Kuijpers, MD, PhD, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands. t.w.kuijpers@ 123456amc.nl
                [∗∗ ]James E. Thaventhiran, MRCP, FRCPath, PhD, Addenbrooke's Hospital (Box 157), Hills Rd, Cambridge CB2 0QQ, United Kingdom. jedt2@ 123456cam.ac.uk
                [∗]

                These authors contributed equally to this work.

                [‡]

                These authors contributed equally to this work.

                Article
                S0091-6749(18)30286-0
                10.1016/j.jaci.2018.01.039
                6148345
                29477724
                3f715965-b0d6-43fe-97a0-17330606c85b
                © 2018 The Authors

                This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

                History
                : 13 April 2017
                : 15 December 2017
                : 3 January 2018
                Categories
                Article

                Immunology
                b cells,common variable immunodeficiency,nuclear factor κb1,cfse, carboxyfluorescein succinimidyl ester,cvid, common variable immunodeficiency,lof, loss-of-function,nf-κb, nuclear factor κb,nfkb1, nuclear factor κb subunit 1,nihrbr-rd, nihr bioresource–rare diseases,pid, primary immunodeficiency disease,pml, progressive multifocal leukoencephalopathy,rhd, rel homology domain,vep, variant effect predictor

                Comments

                Comment on this article